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Abstract
Background: Actinobacillus actinomycetemcomitans’ lipopolysaccharide (LPS) has a high virulence factor. It interacts 
with serum protein through receptors on the epithelial cell surface, thereby increasing both interleukin (IL)-1β, and IL-6 
which results in damage to periodontal tissue.
Aim: The aim of the study was to identify and evaluate the effect of LPS derived from local isolates (A. actinomycetemcomitans) 
on the destruction of alveolar bone by means of several biomarkers, including; the number of osteoblasts and osteoclasts, the 
expression of IL-6, matrix metallopeptidase 1 (MMP-1), and receptor activator of nuclear factor kappa-Β ligand (RANKL).
Materials and Methods: The isolation of LPS from A. actinomycetemcomitans was calculated using phenol, while 
purification was performed using Sephadex C-18 column chromatography. 40 Wistar rats were divided into four groups of 
10. Each treatment was divided into two groups which were 0.9% NaCl and LPS induced for 7 and 14 days, respectively.
Gingival and alveolar bones were further introduced into the induction area, followed by the measuring of osteoblast and 
osteoclast with hematoxylin-eosin staining, IL-6, MMP-1 and RANKL expression with immunohistochemical.
Results: Reduced numbers of osteoblasts at the 7th and 14th day of treatment were detected, while those of osteoclasts increased. 
There was an increased expression of IL-6, MMP-1, and RANKL in the 7th and 14th-day treatment group. Treatment of LPS 
from A. actinomycetemcomitans over 7 and 14 days resulted in damage to periodontal tissue and alveolar bone in Wistar rats.
Conclusion: LPS of A. actinomycetemcomitans administration for 7 and 14 days causes periodontal and alveolar tissue 
destruction in Wistar rats.
Keywords: Actinobacillus actinomycetemcomitans local isolate, lipopolysaccharide, interleukineIL-6, matrix 
metallopeptidase-1, receptor activator of nuclear factor kappa-Β, receptor activator of nuclear factor kappa-Β ligand.
Introduction
Lipopolysaccharide (LPS) is a component of 
A. actinomycetemcomitans forming its cell wall as 
a virulence factor. LPS interacts with serum protein 
through receptors on the epithelial cell surface [1]. 
The high concentration of LPS increases interleukin 
(IL) - 1β and IL-6 which, in turn, results in the destruc-
tion of periodontal tissue due to a cytokine response in 
the epithelium, neutrophil, fibroblast, and monocyte. 
The process occurs through host stimulation and plays 
an important role in tissue damage by stimulating the 
macrophage to release (IL-1), IL-1β, and tumor necro-
sis factor (TNF). These pro-inflammatory cytokines 
are responsible for causing bone damage [2].
The LPS interferes with the homeostasis of colla-
gen metabolism through collagen phagocytosis through 
fibroblast. A study by Shaddox et al. [3], found that LPS 
stimulates the synthesis of osteoblastic IL-1β, TNFα, 
IL-6, and receptor NF-кB ligand (RANKL). The viru-
lence potential of the A. actinomycetemcomitans might 
be different. Specific Polysaccharide Antigen (SPA), 
serotype b of A. actinomycetemcomitans is respon-
sible for the resistance mechanism to phagocytosis 
and kills polimorfonuclear leukocyte in humans [4]. 
Takahashi et al. [4] reported that the SPA of serotype 
a and c induces IL-1 release by murine’s macrophage 
which is lower than the SPA of A. actinomycetemcom-
itans serotype b. Meanwhile, Patil et al. [5] demon-
strated the higher sensitivity of various antimicrobials 
in other serotypes compared to that of A. actinomyce-
temcomitans. Some kinds of yeasts secrete toxins and 
these types called killer yeasts. These yeasts can inhibit 
the growth of other yeast strains and also have antimi-
crobial activities inhibiting growth of bacteria [6,7].
The aims of this study were to determine the 
effect of LPS in a local isolate of A. actinomycetem-
comitans, as characterized by several markers of dam-
aged alveolar, through the measuring of osteoblast and 
osteoclast, as well as IL-6, Matrix Metallopeptidase 1 
(MMP-1) and RANKL expression.
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Materials and Methods
Ethical approval
This study received an ethical clearance approval 
letter relating to human subjects from the Ethics 
Research Committee of Faculty of Dental Medicine, 
Universitas Airlangga, with number 29/KKEPK/
FKG/III/2015. The research constituted Analytical 
Observational involving the use of an Experimental 
Laboratory and a cross-sectional method.
A. actinomycetemcomitans local isolate preparation
A. actinomycetemcomitans was obtained from 
patients with aggressive periodontitis and further sub-
cultured in Luria Berthani (Merck KgaA®, Darmstadt, 
Germany) for 2-3 days to obtain its morphology (visu-
alized in 2 plates). An A. actinomycetemcomitans cul-
ture of 200 µl was required for four animal model 
groups (40 rats in total); therefore, 10 ml culture was 
stored at a density of 108 cells every day for a period 
of 14 days. 200 µl LPS of A. actinomycetemcomitans 
was produced containing 200 µg/ml proteins to induce 
sulcus of the maxilla molar of Wistar rats over 7th day 
to 14th day. LPS was isolated and purified following 
Westphal and Jann’s [6] phenolic-based method. The 
resulting purified crude LPS and isolate were sub-
sequently gel-filtrated in Sephadex® C-18 (Sigma 
Aldrich™, Darmstadt, Germany) at room tempera-
ture with a disaggregation buffer as solvent (0.05 M 
Tris-HCl pH 9, 0.001 M EDTA, and 0.3 deoxycholate) 
(Sigma-Aldrich™, Darmstadt, Germany).
Animal model study preparation
The animal model used consisted of Wistar rats 
divided into four groups each containing 10 rodents. 
Group 1 constituted a control group, induced with 
NaCl 0.9% for 7 days Group 2 received treatment with 
LPS for 7 days. Group 3 was induced with NaCl 0.9% 
for 14 days, while Group 4 underwent treatment with 
LPS for 14 days [4,5].
Treatment was injected into the sulcus of the 
first maxillary molar (M1) following Dumistrescu’s 
method [8,9]. Each group was divided into two sub-
groups, one treated for 7 days, the other for 14 days. 
Injections of 200 µg of LPS, with a protein level of 
200 µg/ml, and a density of 108 were administered for 
at least 7 days to obtain significant aggressive peri-
odontitis symptoms [9]. Gingival and alveolar bones 
were subsequently examined into the induction area, 
followed by the measuring of osteoblast and osteo-
clast with hematoxylin-eosin (HE) staining, and IL-6, 
MMP-1, and RANKL expression with an immuno-
histochemical marker kit (Merck KgaA®, Darmstadt, 
Germany).
At the next immunohistochemical examination 
on glass object with 50% glycerin dropped above the 
glass object and viewed the results with an Electron 
Microscope (Automated Electron Microscope, 
Olympus®, USA). Data in normal distribution were 
analyzed using Shapiro-Wilk test (p>0.05).
 Statistical analysis
Data homogeneity was analyzed using ANOVA 
(p<0.05). Statistical analysis was effected by means 
of Statistical Package for the Social Sciences (SPSS) 
17.0 software for windows 8.1 by SPSS Inc., Chicago, 
United States.
Results
Measurement of osteoblast and osteoclast
The measurement of osteoblast from alveolar 
bones on day 7 showed data were normally distributed 
and homogenous with a significant value of p>0.05. 
ANOVA analysis showed there was a considerable 
difference on day 7 in the osteoblast between the treat-
ment group 16.5±3.84 and the control group 5±0.82 
(p<0.05). Measurement of osteoblast from alveolar 
bones carried out on day 14 showed was normally dis-
tributed and homogenous p>0.05. ANOVA analysis 
showed there was a marked difference in osteoblast 
between the treatment group 22.6±2.41 on day 14 and 
that of the control group 5.8±1.48 (p<0.05).
The measurement of osteoclast from alveolar 
bones on day 7 showed data to be normally distributed 
and homogenous p˂0.05. ANOVA analysis showed 
there was a no stable contrast in osteoclast between 
the treatment group on day 7 and the control group 
(p<0.05). The measurement of osteoclast from alveo-
lar bones on day 14 confirmed that data were normally 
distributed and homogenous with a significant value 
of p˃0.05. ANOVA analysis showed there was a con-
siderable difference in osteoclast between the treat-
ment group on day 14 and the control group (p<0.05).
A graphic of the average alveolar osteoblast on 
day 7 showed 15 cells in the control group and 7.4 cells 
in the treatment group. The measurement of osteoclast 
from gingiva tissue on day 7 confirmed there to be 
5 cells in the control group and 16.5 cells in the treat-
ment group. Osteoblast measurements taken from the 
alveolar on day 14 showed that osteoblast represented 
22.6 cells in the control group, but only 4.5 cells in the 
treatment group. The measurement of osteoclast-de-
rived from gingiva tissue on day 14 established the 
presence of 5.8 cells in the control group, in contrast 
to the 22.6 cells in the treatment group. The average 
presence of osteoblast and osteoclast in the alveolar 
bone can be seen in Figure-1, while the results of HE 
staining of gingiva tissue are shown in Figure-2.
Expression of IL-6, MMP-1, and RANKL
The expression of IL-6 in gingival tissue during 
day 7 showed data were normally distributed and 
homogenous (p>0.05). ANOVA analysis revealed 
a significant difference of IL-6 expression between 
the day 7 treatment group 15.8±0.79 and the con-
trol group 4.7±1.16 (p<0.05). The expression of 
IL-6 from gingival tissue undergoing day 14 treat-
ment showed the data to be normally distributed and 
homogenous (p>0.05). ANOVA analysis negated any 
significant difference of IL-6 expression between 
Veterinary World, EISSN: 2231-0916 163
Available at www.veterinaryworld.org/Vol.11/February-2018/11.pdf
the day 14 treatment group 2.1±0.74 and the control 
group 1.9±0.74 (p<0.05). The average IL-6 expres-
sion in gingival tissue is shown in Figure-3, while the 
result of IHC staining of Wistar rat gingiva features in 
Figure-4.
The data of MMP-1 expression in gingiva in day 
7 treatment were normally distributed and homogenous 
(p>0.05). ANOVA analysis confirmed a considerable 
difference in IL-6 expression between the day 7 treat-
ment 15.3±0.67 and control groups 6.1±0.99 (p<0.05). 
The data of MMP-1 expression in gingiva during day 14 
treatment were normally distributed and homogenous 
(p>0.05). ANOVA analysis confirmed a significant dif-
ference in IL-6 expression between the day 14 treat-
ment group 5.9±0.74 and the control group 3.9±0.74 
(p<0.05). The average MMP-1 expression in gingival 
tissue is shown in Figure-5, with the result of IHC stain-
ing of Wistar rat gingiva contained in Figure-6.
The data of RANKL expression in gingiva after 
treatment lasting 7 days was normally distributed and 
homogenous (p>0.05). ANOVA analysis showed there 
was a significant difference in RANKL expression 
between the day 7 treatment group 15±2.5 and the con-
trol group 10.1±2.5 (p<0.05). Data relating to RANKL 
expression in gingiva after 14-day treatment was nor-
mally distributed and homogenous (p>0.05). ANOVA 
analysis showed there to be a significant difference 
in RANKL expression between the day 14 treat-
ment group 18.8±1.03 and the control group 15±1.2 
(p<0.05). The average RANKL expression in gingiva 
is shown in Figure-7 with the result of IHC staining of 
Wistar rat gingiva contained in Figure-8.
Discussion
The highest concentration of osteoblasts in the 
alveolar bone was found in the day 14 control group 
and differed significantly compared to that of the 
treatment group. These results occurred due to the 
absence of aggressive periodontitis which, in contrast, 
was found to be present in the LPS treatment group. 
Osteoblast plays an important role in mineralization 
and hydroxyapatite precipitation by regulating cal-
cium and phosphate levels during the composition of 
hydroxyapatite. Osteoblast produces alkaline phos-
phatase in adequate amounts in the plasma mem-
brane responsible for bone mineralization. Osteoblast 
also produces cytokines such as colony stimulating 
Figure-1: Average levels of osteoblast and osteoclast in 
treatment on days 7 and 14 in alveolar bone.
Figure-2: Hematoxilin-Eosin staining of gingiva tissue. 
Control (a); with 7-day induction of lipopolysaccharide 
(LPS) (b); Group with 7-day induction of LPS (c). The black 
arrow indicates osteoclast, while the yellow shows the 
location of osteoblast.
Figure-3. Average interleukin-6 expression in gingival 
tissue.
Figure-4: Expression of interleukin-6 in gingiva of Wistar 
rat. Control (a); Actinobacillus actinomycetemcomitans 
lipopolysaccharide (LPS) (day 7) (b); A. actinomy 
cetemcomitans LPS (day 14) (c), indicated by the brown 
regions in the nucleus (black arrow). Activated expression 
of interleukin -6 was shown as brown in cytoplasm of 
gingiva epithelium (black arrow) at 400× magnification.
a b
c
a b
c
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factor-1, RANKL, and osteoprotegerin [8-10]. The 
highest concentration of alveolar osteoclast was found 
in the day 14 LPS treatment group and differed con-
siderably compared to that of the control group.
The induction of LPS causes adhesion and invasion 
in the host. LPS is a major factor in bacteria and plays 
an important role in bone resorption through osteoclast 
stimulation in which LPS activates osteoblast to release 
factors attracting and activating osteoclast [11]. LPS 
can make macrophages activated, and can also trig-
ger the synthesis o-f both cytokines that have pro-in-
flammatory activities, such as interleukin (IL)-1, IL-6, 
IL-8, and TNF α, as well as another cytokine, namely, 
IL-10 serving as regulator [2,3,12]. LPS also inhibits 
collagen and non-collagen protein synthesis. Referring 
to a study conducted by Takahashi et al [4] and Nair 
et al. [13] found that the LPS of A. actinomycetemcomi-
tans causes bone resorption in murine calvarial by stim-
ulating murine macrophage. A. actinomycetemcomitans 
causes alveolar bone destruction and antibody response 
in three rat strains; Fawn Hooded Hypersensitive, Dahl 
Salt Sensitive, and Norway Brown [14].
The process of periodontitis passes through 4 
phases: (1) Accumulation and presence of bacteria 
in gingival sulcus (colonization); (2) bacterial inva-
sion of the epithelium and gingiva; (3) host response 
stimulation, acquired and innate (inflammation) 
immune response activation; and (4) destruction of 
connective tissue attachment on dental enamel and 
bone causing irreversible damage [1]. The presence 
of LPS decreases osteoblast. LPS generates stim-
ulation on RANKL which further binds to RANK, 
stimulating tumor necrosis receptor-associated fac-
tors-6 for osteoclast progenitor activation leading to 
osteoclast differentiation, activation and an increased 
number of osteoclasts. This, in turn, causes alveolar 
bone destruction which can serve as a marker if such 
destruction has occurred [15].
IL-6 expression in gingiva during day 7 treat-
ment showed an increase and a marked difference 
compared to the control, indicating the presence of 
LPS in periodontal tissue. LPS stimulates pro-inflam-
matory cytokine activation, such as IL-6, stimulating 
bone resorption, and inhibiting bone formation lead-
ing to periodontal and alveolar damage [2,16].
Figure-5. Average matrix metallopeptidase-1 expression 
in gingiva.
Figure-6: Matrix metallopeptidase-1 (MMP-1) expression 
in gingiva of Wistar rat. Control (a); treatment of 
lipopolysaccharide (LPS) (7-day) (b); treatment of LPS 
(14-day) (c), shown as brown in the nucleus (black arrow). 
Activated MMP-1 expression is highlighted as brown in 
cytoplasm of gingiva epithelium (black arrow) at 400× 
magnification.
Figure-7: Average receptor activator of nuclear factor 
kappa-Β ligand expression in alveolar.
Figure-8: Expression of receptor activator of nuclear 
factor kappa-Β ligand in alveolar of Wistar rat. Control (a); 
Actinobacillus actinomycetemcomitans lipopolysaccharide 
(7 days) (b); A. actinomycetemcomitans (14 days) 
(c), shown as brown in the nucleus (black arrow) at a 
magnification of 400×.
a b
c
a b
c
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The expression of MMP-1 in the day 7 and day 
14 treatment groups showed a significant contrast 
compared to that of the control group. The induction 
of LPS A. actinomycetemcomitans causes pro-inflam-
matory cytokine stimulation. IL-8 produced by mono-
cyte, keratinocyte, endothelial, and fibroblast cell 
stimulates the release of MMPs by neutrophil. One 
such MMP was MMP-1 which is a potential collage-
nase-1 and plays a role in the degradation of connec-
tive tissue in the inflamed area. The high expression 
of MMP-1 provokes periodontal and alveolar damage 
in accordance with the study conducted by Claesson 
et al. [17] that confirmed A. actinomycetemcomitans 
to be a strong stimulant to MMP-8 release, mainly due 
to Leukothera being one of its 15 virulence factors.
The expression of RANKL in alveolar bones tends 
to increase and shows a significant difference in the day 
7 and day 14 treatment groups compared to the control 
group. The result confirms LPS-l as an antigenic compo-
nent raising host immune response and further stimulat-
ing pro-inflammatory cytokines, especially TNF-α and 
IL-1. TNF-α and IL-1 stimulate RANKL which increase 
osteoclast. The high expression of osteoclast augments 
osteocalcin that can lead to alveolar bone resorption. 
A previous study conducted by Bullon et al. [18], posited 
that the increased number of osteocalcins was a marker 
of bone formation inhibition. An elevation osteocal-
cin level in serum was associated with the rate of bone 
destruction. Studies involving animals confirmed the 
role of osteocalcin in alveolar bone resorption.
Conclusion
LPS induces IL-6 expression, osteoclastogene-
sis, and bone resorption. Injection of porphyromonas 
gingivalis from IL-6-removed rats causes a reduced 
level of bone loss. This implies that IL-6 contributes 
to bacteria progressivity which promotes alveolar 
damage. RANKL regulates the pathological and phys-
iological conditions of bone resorption. During the 
pathological inflammation phase of the bone disease, 
RANKL expression was found to be present in B cell, 
T cell, and monocyte. Activation of T-cell and B-cells 
are cellular sources of RANKL in bone resorption in 
gingiva during inflammation. These results support 
the conclusion that LPS of A. actinomycetemcomitans 
administration over day 7 and day 14 causes periodon-
tal and alveolar damage in Wistar rats.
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